In 2024_News_Viwit

News

/

/

In 2024

News Classification

Check category



News Center

Viwit’s Levetiracetam Tablets Approved by FDA 2024-04-09 11:28:41

On April 5, 2024, Viwit Pharmaceuticals' Levetiracetam Tablets received an Approval Letter (#078869) from the U.S. Food and Drug Administration (FDA), marking Viwit's first approved oral solid dosage in the United States.

Viwit Pharmaceuticals' Mirabegron API Receives Official Approval by China NMPA 2024-01-26 11:09:29

On January 23, 2024, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for its own proprietary active pharmaceutical ingredient (API) Mirabegron, developed independently. The issued registration number is Y20220000096, and the corresponding notice number is 2024YS00039.

Viwit Pharmaceuticals' Vildagliptin Tablets Receive Official Approval by China NMPA 2023-12-22 13:19:44

Viwit Pharmaceuticals is pleased to announce the acquisition of the Drug Registration Certificate (Certificate No: 2023S01974) from the National Medical Products Administration (NMPA) for a proprietary finished dosage form, Vildagliptin tablet. This signifies the official approval of this product in the Chinese market.

Viwit Pharmaceuticals' Lidocaine Injection Receives Official Approval by China NMPA 2023-12-19 11:25:05

On December 18, 2023, Viwit Pharmaceuticals received the "Drug Supplementary Application Approval Notice" (Notice No: 2023B06224) issued by the China National Medical Products Administration for a proprietary finished dosage form, Lidocaine Hydrochloride for Injection (5ml: 0.1g).

Viwit Pharmaceuticals' Vildagliptin API Receives Official Approval by China NMPA 2023-12-07 08:31:28

On November 30, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by National Medical Products Administration (NMPA) for its independently developed active pharmaceutical ingredient (API), Vildagliptin. The registration number is Y20210000619, and the notice number is 2023YS00803.

Viwit Pharmaceuticals' Aprepitant API Receives Official Approval by China NMPA 2023-10-31 15:33:57

On October 26, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for the independently developed active pharmaceutical ingredient (API) Aprepitant. The registration number is Y20210000473, and the notice number is 2023YS00727.

In 2024

04-09 

Viwit’s Levetiracetam Tablets Approved by FDA

On April 5, 2024, Viwit Pharmaceuticals' Levetiracetam Tablets received an Approval Letter (#078869) from the U.S. Food and Drug Administration (FDA), marking Viwit's first approved oral solid dosage in the United States.

Viwit’s Levetiracetam Tablets Approved by FDA

01-26 

Viwit Pharmaceuticals' Mirabegron API Receives Official Approval by China NMPA

On January 23, 2024, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for its own proprietary active pharmaceutical ingredient (API) Mirabegron, developed independently. The issued registration number is Y20220000096, and the corresponding notice number is 2024YS00039.

Viwit Pharmaceuticals' Mirabegron API Receives Official Approval by China NMPA

Previous page

1

Next page



search

Confirm

Close

About Us

R&D and Innovation

Products

Innovation

Sustainable

News Center

Join Us

Contact Us

VIWIT 沪ICP备12014533号-2 Terms of Use

EN

中文